Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 4

1(14.3%)

Phase 2

1(14.3%)

N/A

1(14.3%)

7Total

Phase 1(4)

Phase 4(1)

Phase 2(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT01188512Phase 1Completed

First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine

Role: collaborator

NCT01064375Phase 1Completed

Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer

Role: collaborator

NCT01697007Phase 2Completed

A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique

Role: collaborator

NCT01461447Phase 1Completed

Safety Study of an Additional MVA Vaccine in Volunteers Who Received 3 DNA Vaccines Followed by 2 MVA Vaccines

Role: collaborator

NCT01140139Phase 1Completed

Dermal HIV-1 Immunization During Anti-retroviral Therapy Followed by Repeated Treatment Interruptions

Role: lead

NCT00870350Phase 4Unknown

An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster

Role: lead

NCT00927316Not ApplicableCompleted

E. Coli 83972 Induced Asymptomatic Bacteriuria (ABU) in Patients With Recurrent Urinary Tract Infections (UTI)

Role: collaborator

NCT00932269Unknown

Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease

Role: lead

All 8 trials loaded